| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPA3 |
| Uniprot No | P15088 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 110-417aa |
| 氨基酸序列 | IPGRHSYAKYNNWEKIVAWTEKMMDKYPEMVSRIKIGSTVEDNPLYVLKIGEKNERRKAIFTDCGIHAREWVSPAFCQWFVYQATKTYGRNKIMTKLLDRMNFYILPVFNVDGYIWSWTKNRMWRKNRSKNQNSKCIGTDLNRNFNASWNSIPNTNDPCADNYRGSAPESEKETKAVTNFIRSHLNEIKVYITFHSYSQMLLFPYGYTSKLPPNHEDLAKVAKIGTDVLSTRYETRYIYGPIESTIYPISGSSLDWAYDLGIKHTFAFELRDKGKFGFLLPESRIKPTCRETMLAVKFIAKYILKHTS |
| 预测分子量 | 38.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CPA3(羧肽酶A3)重组蛋白的3篇参考文献示例(注：文献信息为模拟示例，实际引用时请核实真实来源)：
1. **《Recombinant human CPA3: characterization of substrate specificity and role in mast cell-mediated inflammation》**
- 作者：Smith A, et al.
- 摘要：本研究成功在大肠杆菌中表达并纯化了重组人CPA3蛋白，分析了其对不同肽类底物的酶活性，发现CPA3特异性降解含C末端芳香族氨基酸的底物。实验证明，CPA3通过调节组胺释放参与肥大细胞介导的过敏性炎症反应。
2. **《Structural insights into CPA3 activation and its implications in asthma pathogenesis》**
- 作者：Zhang L, et al.
- 摘要：通过X射线晶体学解析了重组CPA3的活化结构，揭示了其前体形式(pro-CPA3)向活性酶的转化机制。研究进一步发现，CPA3在哮喘患者肺组织中的表达上调，可能与气道重塑和炎症相关。
3. **《CPA3重组蛋白在肿瘤微环境中的免疫调节作用》**
- 作者：Wang Y, et al.
- 摘要：利用昆虫细胞表达系统制备了高活性CPA3重组蛋白，发现其能选择性降解肿瘤微环境中的纤维连接蛋白，抑制巨噬细胞M2型极化，为靶向CPA3的肿瘤免疫治疗提供了实验依据。
**提示**：实际文献可通过PubMed或Google Scholar检索关键词“CPA3 recombinant protein”、“Carboxypeptidase A3 expression”或结合具体研究领域(如肥大细胞、过敏、癌症)筛选。部分真实文献可能包括：
- Pejler G, et al. 对CPA3在肥大细胞分泌颗粒中功能的经典研究(*J Biol Chem*)。
- Schneider E, et al. 关于CPA3基因调控的报道(*Allergy*)。
Carboxypeptidase A3 (CPA3), also known as mast cell carboxypeptidase A, is a zinc-dependent metalloprotease primarily expressed in mast cells. It belongs to the carboxypeptidase gene family, which plays roles in processing bioactive peptides by cleaving C-terminal amino acids. CPA3 is stored in mast cell secretory granules alongside other mediators like histamine and tryptase, and it is released during mast cell degranulation in response to allergic or inflammatory stimuli.
Originally identified as a mast cell-specific enzyme, CPA3 is encoded by the CPA3 gene in humans. Its precursor form requires proteolytic activation to become enzymatically active. Unlike other carboxypeptidases, CPA3 exhibits unique substrate specificity, preferentially cleaving aromatic or branched-chain aliphatic residues. This enzymatic activity contributes to the regulation of peptide hormones and inflammatory mediators, potentially influencing processes such as tissue remodeling, host defense, and anaphylaxis.
Recombinant CPA3 proteins are produced using biotechnological platforms (e.g., bacterial, insect, or mammalian expression systems) for research and therapeutic applications. These engineered proteins retain catalytic activity while enabling controlled production for functional studies. Current research focuses on CPA3's involvement in allergic diseases (asthma, anaphylaxis), mastocytosis, and cancer progression, where abnormal CPA3 levels correlate with disease severity. Its role in processing matrix proteins and bioactive peptides also suggests potential applications in biomarker development and targeted therapies. However, the complete physiological spectrum of CPA3 remains under investigation, particularly regarding its dual roles in protective immunity and pathological inflammation.
×
